Redacted
Version

[**]
CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED
PORTIONS.

EXHIBIT 10.210

CONTRACT MANUFACTURING AGREEMENT

THIS
CONTRACT MANUFACTURING AGREEMENT (the "Agreement") is made and entered into as ofJuly 26, 2001("Date of Agreement"), by and between:

Chiron S.p.A., with its registered offices at Via Fiorentina 1, 53100 Siena, Italy, hereafter referred to as "Chiron",

and

SynCo Bio Partners B.V., with its registered offices at Paasheuvelweg 30, 1105 BJ Amsterdam Zuidoost, The Netherlands, hereafter
referred to as the"SynCo".

Background


Chiron has developed or is developing a broad line of novel adult and pediatric vaccines for viral and bacterial infectious diseases;


SynCo operates a manufacturing plant in Amsterdam, The Netherlands;


Chiron wishes to contract with SynCo to provide services related to the production of certain vaccines or intermediate products in the Plant, in quantities and at times to be separately
agreed upon between Parties. SynCo is willing to use its personnel, expertise and facilities to discharge such contract manufacturing tasks and to provide such services, assistance, advice and
consulting as Chiron may request from time to time.

NOW,
THEREFORE, in consideration of the premises, the mutual covenants, terms and conditions hereinafter set forth, THE PARTIES AGREE AS FOLLOWS:

Article 1Definitions

For
the purpose of this Agreement the following terms shall be defined as follows:

---

Article 2Manufacture of Product



Article 3Transfer of Technology and Material.

[**]
CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED
PORTIONS.

2

---

Article 4Regulatory Affairs and Quality Assurance

3

---



Article 5Warranties and Liability

EXCEPT
AS OTHERWISE EXPRESSLY PROVIDED HEREIN, SYNCO MAKES NO WARRANTIES EXPRESS OR IMPLIED AND EXPRESSLY DISCLAIMS WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE OR MERCHANTABILITY, AND SYNCO SHALL
NOT BE LIABLE FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES IN ANY CASE OF NONCONFORMITY. NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES ARISING FROM ANY ALLEGED OR
ACTUAL BREACH OF THIS AGREEMENT.

4

---

Article 6Considerations and Payments

Article 7Confidentiality and Intellectual Property

A
Party receiving Confidential Information from the other Party or developing Confidential Information hereunder shall not disclose such Confidential Information to any third party or
otherwise for a period extending ten (10) years following expiration or earlier termination of this Agreement, except as follows:



[**]
CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED
PORTIONS.

5

---



For
the avoidance of doubt: It is understood that SynCo purchased the Plant and certain related equipment, including computers and other information technology systems, from an Affiliate of Chiron,
and that prior to such purchase the Plant and equipment were utilized by Chiron and its Affiliates for the manufacture of Products. It is further understood that certain employees of SynCo formerly
were employees of an Affiliate of Chiron and were engaged directly or indirectly in the manufacture of Products. Notwithstanding anything to the contrary contained herein, and in particularly
notwithstanding paragraph (b) above, all information relating the Specifications, Technology or manufacture of the Products which exists as of the date of this Agreement shall be owned solely
and exclusively by Chiron and shall not be disclosed by SynCo at any time during the term of this Agreement or for a period of ten years following the expiration or earlier termination of this
Agreement.

Each
Party shall use Confidential Information received from the other Party solely for the purposes of this Agreement and for no other purpose whatsoever.

Article 8Term of Agreement

The
term of this Agreement shall commence as of the Date of Agreement, and will continue untilJanuary 1, 2004. Termination of this agreement
will not relieve Chiron of its obligations to pay SynCo for Product previously supplied hereunder and for commitments which arise directly out of firm purchase orders for Products and which cannot
reasonably be canceled or otherwise put to use.

Article 9Additional Terms

6

---

IN
WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by their duly authorized representatives:

|Chiron S.p.A.                                               |  |  |  | SynCo Bio Partners B.V.                            
|----------------------------------------------------------- |  |  |  | ---------------------------------------------------
|/s/GABRIELE BRUSADr. Gabriele Brusa Chief Executive Officer |  |  |  | /s/MIC N. HAMERSDr. Mic N. Hamers Managing Director

7

---

APPENDIX A    COST OF CERTAIN PRODUCT

The
[**] of dried purified MenC polysaccharides amounts to [**] for the year [**]

The
[**] of CRM197 amounts to [**] for the year [**] and amounts to for the year [**]

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH
RESPECT TO THE OMITTED PORTIONS.

---

APPENDIX B    LIST OF PRODUCTS

MEN
C
CRM197

---

APPENDIX C    OPERATING PROCEDURES AND SPECIFICATIONS

MF-MFS-MEC-000        Master
Formulation Document MenC polysaccharide This document lists all materials, documents, including all BPRs and control methods and equipment for the production of MenC

MF-MFS-CRM-000        Master
Formulation Document for CRM197 This document lists all materials, documents, including all BPRs and control methods, and equipment for the production of CRM197

---

APPENDIX D    FIRM ORDERS

Campaign of [**]

[**]
for registration purposes.
Campaign shall start no later than [**]

Campaign of [**]

[**]
Delivery preferably in [**], but not later [**]

Campaign of [**]

[**]
Delivery preferably in [**], but not later than [**]

N.B.
[**] can be (partly) changed to [**]. If the order is [**] of [**].

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH
RESPECT TO THE OMITTED PORTIONS.

---

QuickLinks